Trials / Completed
CompletedNCT01029613
Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers
Adalimumab in Rheumatoid Arthritis. An Investigation of Changes in Disease Activity and Course of Joint Destruction by Use of 3 Tesla Whole-Body MRI, Dedicated 3 Tesla MRI and CT of the Hand, and Soluble Biomarkers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Glostrup University Hospital, Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers. Furthermore to compare ultrasound examination with wholebody MRI etc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab | sc. inj. Humira 40 mg every other week from week 0 to 52 |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2009-12-10
- Last updated
- 2015-08-19
Locations
8 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01029613. Inclusion in this directory is not an endorsement.